Immunicum: Positive Safety Update from ILIAD Combination Trial - Redeye

Redeye believes the update from the ILIAD trial confirms the strong safety profile of ilixadencel, notably now also in combination with checkpoint inhibitors. While we have to wait a bit longer for a full update, including, e.g., efficacy data, we expect a positive reaction to the news.

https://www.redeye.se/research/817716/immunicum-positive-safety-update-from-iliad-combination-trial?utm_source=finwire&utm_medium=RSS